Ingersoll Rand Inc. (NYSE: IR) — Organic Growth Returned; Capital Returns Still Haven’t

Independent equity research

Report date: 2026-08-26 · Update of: prior analysis dated 2026-06-26 · Price reference: $78.57 (2026-08-25 close)

Sector: Industrials / General Industrial Machinery · CIK: 0001699150 · Fiscal year: December

Except for the clearly fenced Claude’s Take below, this institutional analysis carries no recommendation and no price target. Facts are sourced to public filings and data as of the report date; management commentary is treated as a hypothesis and tested against reported outcomes.

⚡ Claude’s Take

Claude’s independent subjective opinion, provided for general information; not investment advice. The analytical body below carries no position.

Verdict: HOLD / do not chase; accumulate only on weakness around $65–72, or roughly 14–15.5x trailing adjusted EBITDA. Not a short. Conviction: medium.

The June report called IR a brilliant operator earning its cost of capital. Q2 improves the first half of that sentence without yet fixing the second. Organic revenue accelerated to 4.1%, every major region grew, P&ST orders rose 7.4% organically, and July orders jumped double digits as delayed projects closed. IR also showed better capital discipline than the prior memo gave it credit for: it recovered an initial $187.5 million on the ILC Dover representations-and-warranties claim and walked away from an approximately $1 billion target over valuation. Those are real positives. They are why the preferred accumulation band moves modestly above the prior high-$50s/high-$60s zone.

Yet the quarter did not produce the economic conversion the bull case needs. Adjusted EBITDA rose only 2.1% on 8.5% reported revenue growth, margin fell 160 basis points, first-half free cash flow was flat despite 8.1% revenue growth, and the full-year EBITDA/EPS ranges were not raised. Adjusted EPS grew 7.5%, but adjusted net income grew only 4.5% and a 2.8% lower diluted share count did part of the work. Full-capital ROIC remains approximately 8% on a balance sheet with negative tangible equity—near, not above, a reasonable 9–10% cost of capital. At roughly 16.2x trailing adjusted EBITDA and 22x the high end of 2026 adjusted EPS, the stock is no longer expensive relative to quality-industrial peers, but it is still priced for the acquisition flywheel to work indefinitely. Framing: a de-rated quality operator in a show-me phase, not a washed-out value stock.

Conviction: medium. Bullish flip: two more quarters of at least 3% organic growth accompanied by at least 30% incremental adjusted EBITDA margin and a clearly rising all-in ROIC. Bearish flip: organic orders return to zero or negative, the promised second-half margin recovery fails, or another large platform deal adds goodwill without improving returns.

📈 Stock Price Action — Five-Year Event Map

IR compounded from roughly $52 in August 2021 to an adjusted all-time high of $105.85 on 2024-11-25, then de-rated to $78.57. The current price is 25.8% below that peak and sits inside a trailing-52-week adjusted range of $68.05–$100.89. It is below the 21-, 50-, and 200-day EMAs of $82.81, $81.80, and $81.53. The five-year gain is still approximately 52%, but the trailing year is -1.3% and the trailing six months -16.8% (AZI daily price CSV, accessed 2026-08-26).

The modern IR price cycle began with the 2020 Gardner Denver/Ingersoll-Rand Industrial combination and a large operating-system rerating. The stock’s 2022–2024 advance was earned by extraordinary margin improvement, but the 2024–2026 round trip shows the market now demands organic conversion, not only adjusted-EPS accretion. The Q2-2026 print produced a telling two-step: the stock opened down roughly 5% on July 31, recovered to almost $90 by August 5 as investors absorbed the strong July-order commentary, then surrendered the entire gain. That is a show-me tape—neither a momentum one-way street nor capitulation.

1. Executive Summary

Ingersoll Rand is a global manufacturer and service provider of air and gas compressors, vacuum pumps, blowers, industrial tools, precision pumps, fluid-management systems, and life-science components. FY2025 revenue was $7.651 billion; trailing revenue through Q2-2026 reached $7.942 billion. The company operates through Industrial Technologies & Services (ITS), roughly four-fifths of sales, and Precision & Science Technologies (P&ST), roughly one-fifth. The 2020 reverse-Morris-trust combination of Gardner Denver and the old Ingersoll-Rand industrial segment created the current enterprise. CEO Vicente Reynal runs it through Ingersoll Rand Execution Excellence, or IRX, a decentralized operating system combining 80/20 portfolio management, pricing, sourcing, productivity, and acquisition integration (FY2025 10-K, filed 2026-02-17).

The good business is visible. ITS aftermarket was about 40.6% of segment sales in 2025; consolidated aftermarket was about 36% in Q2-2026. A compressor can generate more aftermarket revenue across its useful life than its initial equipment sale. That installed-base annuity supports service density, OEM-fit parts, customer familiarity, and uptime-based switching costs. P&ST adds structurally attractive niches in metering, dosing, water, medical, biopharma, and engineered materials. Gross margin expanded from 35.4% in 2020 to 43.6% in 2025, while GAAP operating margin rose from 6.9% to 19.7%. Few large industrial operators have improved their income statement so dramatically in five years.

The investment controversy is not whether IRX works. It plainly works on acquired businesses and the cost structure. The controversy is whether the corporation captures value after paying for those businesses. From 2021 through 2025 IR deployed approximately $5.7 billion on acquisitions. Goodwill and other intangibles stood at $12.61 billion at June 2026—69% of assets and about $2.4 billion above common equity. A straightforward NOPAT divided by debt-plus-equity-less-cash produces roughly 8% full-capital ROIC, compared with an estimated 9–10% WACC. That is far below Greenwald’s 15–25% financial test for a durable franchise. Segment margins can be excellent while shareholders earn only the cost of capital if acquisition premiums absorb the economic rent.

Q2-2026 sharpened, rather than ended, that debate. Revenue grew 8.5% reported and 4.1% organically, but adjusted EBITDA grew 2.1%; margin fell 160 basis points. P&ST was excellent—organic orders +7.4% and margin +200 basis points to 31.5%—while ITS organic orders were flat and margin fell 180 basis points. Management blamed China price/cost, commercial investment, and a corporate-incentive true-up, and expects price/productivity benefits in the second half. That is a testable claim, not an achieved result. First-half FCF was essentially unchanged at $432 million, so the cash statement has not yet validated the revenue inflection (Q2-2026 release, filed 2026-07-30).

Capital allocation improved in observable ways. IR received an initial $187.5 million insurance settlement related to ILC Dover, expects $162.5 million of the remaining amount during 2026, is seeking additional recoveries, and excludes those proceeds from adjusted earnings. The recovery does not erase the impairment, but it reduces the cash loss. More important prospectively, management said it walked away from an approximately $1 billion target because valuation was too high, while announced deals remained bolt-on in nature. The weakness is still governance: the 2026 proxy pays on adjusted EPS, free cash flow, and relative TSR, not ROIC; the absence of a capital hurdle remains structurally awkward for a serial acquirer (2026 proxy, filed 2026-04-24).

At $78.57, using approximately 388 million shares, net debt near $3.60 billion, and trailing adjusted EBITDA around $2.12 billion, equity value is approximately $30.5 billion and EV approximately $34.1 billion—about 16.2x adjusted EBITDA, 4.3x sales, and 22.0x the high end of 2026 adjusted EPS guidance. That is a discount to AMETEK and Parker-Hannifin and closer to Roper/Dover/IDEX territory, but IR’s lower all-in ROIC warrants part of the discount. The stock is fairly valued if organic growth normalizes at 2–3%, margins recover, and bolt-ons create modest value; it remains vulnerable if Q2’s volume improvement cannot convert to cash and returns.

Executive verdict: a very good operator with a narrow installed-base moat, improving demand, and a credible bolt-on system—but no demonstrated corporate-level excess return. The business has improved since June. The evidence required to call it a value compounder has not.

2. Business Overview

Industrial Technologies & Services

ITS sells air and gas compression, vacuum, blower, air-treatment, fluid-transfer, loading, power-tool, and lifting equipment under brands including Ingersoll Rand, Gardner Denver, CompAir, Nash, Elmo Rietschle, and Robuschi. FY2025 revenue was $6.056 billion, 79% of the group, with a 28.9% adjusted segment EBITDA margin. Customers span general industrial, food and beverage, chemicals, oil and gas, power, electronics, transportation, and infrastructure. Products range from configured-to-order shop compressors to engineered centrifugal and oil-free systems.

The recurring economic core is parts and service. Filters, lubricants, seals, controls, air-treatment systems, repairs, and service agreements follow an installed machine over a useful life commonly exceeding a decade. Configuration and application engineering matter: management noted on the Q2 call that even smaller compressors are generally configured or engineered to order, limiting distributor inventory and reducing direct comparability with consumer compressors. That makes local service density and installed-base knowledge more important than corporate brand advertising.

Precision & Science Technologies

P&ST sells precision liquid, gas, air, and powder-handling products for life sciences and industrial applications. Brands include Milton Roy, Dosatron, Seepex, Thomas, Haskel, ARO, Albin, and ILC Dover. Its portfolio covers metering and dosing, progressive-cavity and peristaltic pumps, hydrogen compression, liquid handling, sterile and single-use flow paths, gas analysis, odorization, engineered films, and aerospace/defense products. FY2025 revenue was $1.595 billion, 21% of group sales, with a 30.0% adjusted segment EBITDA margin.

P&ST is economically heterogeneous. Precision Technologies resembles ITS in pumps and shorter-cycle industrial demand, while Life Science Technologies benefits from qualification, validation, and higher failure costs. ILC Dover introduced biopharma single-use products and aerospace/defense, but also the company’s clearest recent acquisition failure. The segment’s Q2-2026 result—31.5% margin and 7.4% organic order growth—shows IRX can improve the remaining assets even after the impairment.

Revenue model and geography

IR sells through direct representatives and independent distributors. Original equipment is tied to industrial capital budgets and project timing; aftermarket follows utilization of the installed base. This combination creates moderate cyclicality: recessions delay equipment, but factories still maintain mission-critical machines. Revenue is globally diversified, with substantial North American, EMEIA, and Asia-Pacific exposure. FX translates reported growth, while local manufacturing partly offsets economic currency risk.

The company is also a capital allocator by design. More than 50 acquisitions since 2021, a funnel exceeding 200 companies, and 11 signed letters of intent at Q2-2026 make deal sourcing an operating process rather than a periodic event. The proper unit of analysis is therefore not only the compressor or pump; it is the acquired-business-plus-purchase-price.

Verdict: understandable, asset-light, service-rich operations with genuine installed-base value. Portfolio breadth dampens volatility, but the corporate model cannot be judged independently of the acquisition premiums that built it.

3. Industry Dynamics

Compressed air is often described as a factory’s fourth utility. That description captures its ubiquity but not market power. The market is mature, global, and fragmented below the leaders. Atlas Copco is the global scale benchmark; IR is a leading challenger and a particularly strong North American participant. Kaeser, Hitachi/Sullair, Elgi, Kaishan, and numerous regional specialists compete in compression. Vacuum and blower competitors include Atlas Copco, Busch, Pfeiffer, and niche suppliers. Precision flow control adds IDEX, Dover, Graco, Roper-owned brands, Watson-Marlow/Spectris, and private specialists.

The profit pool sits in applications, service, and consumables rather than commodity hardware. New original-equipment bids have meaningful price competition. Once a system is installed, however, uptime, parts compatibility, technician availability, process validation, and search cost favor the incumbent. That is why leading compressor companies can earn mid-20s segment margins in an industry whose overall growth is only low-to-mid single digit.

End demand combines cyclical and secular pockets. General industrial, chemicals, oil and gas, and discrete manufacturing follow production and capex. Food, beverage, water, medical, and life sciences are steadier. Power generation, semiconductor air separation, and data-center-related water and cooling infrastructure add new project opportunities, but IR remains a component supplier rather than a pure-play on those themes. Management’s Q2 discussion cited power generation, food and beverage, pharma, air separation, and semiconductors as the delayed long-cycle projects that closed in July. The breadth is more important than any single AI label.

Regulation is not the primary industry barrier, except in product niches: pressure-vessel and safety standards, pharmaceutical validation, environmental rules, water specifications, and aerospace qualification can raise switching cost. Tariffs matter financially through steel, aluminum, components, and region-specific price recovery. Q2 exposed the local nature of pricing power: North American price remained a normal 1–2% while China overcapacity made inflation harder to recover.

Capital-cycle assessment

The operating industry’s supply side is rational at the top and fragmented in the tail. Installed service networks are difficult to recreate quickly, and capex intensity is modest. That is favorable. The adverse capital cycle occurs in the acquisition market. High margins and reliable aftermarket attract Roper, AMETEK, Dover, IDEX, Atlas Copco, private equity, and other strategics to the same niche assets. Competition capitalizes the seller’s economics into the purchase multiple. IR can expand an acquired target’s margin and still earn only WACC if the entry price captured all expected synergies.

This is Marathon’s asset-growth warning in a non-obvious form. IR is not building too many compressor factories; it is accumulating goodwill. The company’s 2026 behavior—low-double-digit pre-synergy bolt-ons, one valuation-based walkaway, and a focus on aftermarket—suggests awareness of the cycle. It does not eliminate the structural pressure.

Industry verdict: structurally good, not great. Mission-critical products, service annuities, and local density protect profit pools; fragmentation, low underlying growth, regional pricing pressure, and competitive acquisition markets prevent a broad franchise moat.

4. Competitive Position

Greenwald’s taxonomy points to customer captivity, not proprietary technology or corporate scale. Switching and search costs arise after installation: customers prefer known technicians, compatible consumables, validated parts, and reliable uptime. The mechanism is observable because ITS aftermarket represents about 41% of segment sales and produces a more stable, higher-margin stream than equipment. Remove that installed-base relationship and ITS margin, retention, and cyclicality would worsen. That passes the financial-outcome test for a moat.

The advantage is narrow. On a new compressor bid, customers can choose among credible global and regional vendors. Technology diffuses, suppliers can imitate efficiency improvements, and Atlas Copco has greater global compression scale. Economies of scale become defensible only where local service density combines with a captive installed base. Thus IR may possess scale in a North American micro-market or a pump niche without possessing a single corporate-wide scale moat.

IRX is a capability, not a barrier to entry. It doubled operating margin, improved acquired companies quickly, and institutionalized sourcing, pricing, and 80/20 decisions. That deserves a valuation premium over an average industrial. But peers use comparable decentralized playbooks; personnel and culture can deteriorate; and a superior operator cannot repeal the purchase price. Operational excellence explains why segment margins rose. The absence of high all-in ROIC explains why it has not yet become a shareholder franchise.

The Greenwald quantitative tests are mixed-to-negative. Market positions appear durable in important niches, but the company does not disclose enough consistent product-level share to demonstrate less than two-point movement across five to eight years. Corporate ROIC around 8% fails the 15–25% moat threshold. Aftermarket share and margin are strong evidence of captivity; consolidated returns show that acquisition premiums redistribute part of that franchise value to sellers.

Against peers, Atlas Copco offers greater compression scale and historically stronger returns. AMETEK and Parker-Hannifin combine decentralized operating systems with more visible organic or all-in economics, though both command richer valuations. Roper offers a higher recurring-software mix but carries leverage and acquisition risk. Dover and IDEX provide closer multiple and niche-flow-control comparisons. IR belongs in the quality-industrial cohort operationally, but toward the lower end on full-capital returns.

Competitive verdict: a narrow durable advantage in installed-base aftermarket and qualified niche applications, reinforced by a valuable operating system. There is no evidence of a broad structural moat at the consolidated-company level.

5. Growth History and Forward Opportunities

Reported growth has been impressive: revenue rose from $3.97 billion in 2020 to $7.65 billion in 2025, a roughly 14% compound rate. Its composition is less impressive. The 2020 merger reset the base; subsequent bolt-ons added billions of purchased revenue; price helped during the inflation cycle; and organic volume turned negative in both 2024 and 2025. The FY2024 bridge included approximately $471 million of acquisition growth and $153 million of price against about $242 million of lower organic volume. FY2025 added roughly $420 million from acquisitions and $92 million of FX while organic revenue declined about $96 million. Those filing bridges show a company growing its perimeter faster than its demand.

Q2-2026 is the first strong counterexample. Consolidated organic revenue grew 4.1%, versus a prior full-year guide midpoint around 1%. ITS grew 4.2% organically, P&ST 3.9%, and every main region was positive. Short- and medium-cycle orders grew mid-single digit. P&ST organic orders rose 7.4%, including low-double-digit Life Sciences and mid-single-digit Precision Technologies. Management raised the full-year organic range to 1–3% and said July orders were double digit after delayed long-cycle projects closed (Q2 release; Q2 webcast).

Three cautions prevent one quarter from becoming a new normalized rate. First, total Q2 organic orders rose only 1.6% and ITS was nearly flat. Revenue can exceed orders temporarily as backlog ships. Second, management explicitly said July’s double-digit rate included project timing and should not be treated as a steady run rate. Third, volume did not convert to margin: adjusted EBITDA grew 2.1% against 8.5% reported sales. The proper growth test is organic revenue plus incremental profit, not the top line alone.

Forward growth engines

Installed-base monetization. Connected monitoring, service agreements, parts, and air-treatment can lift recurring revenue on machines already in the field. This is the highest-quality opportunity because customer acquisition cost is low and captivity already exists. Lone Star Blowers and Fai Filtri explicitly add service, rental, and filter aftermarket.

P&ST scaling. P&ST is approaching the low-30s margin profile management has long targeted, with a mid-30s aspiration. Its life-science, water, dosing, and precision-pump niches offer greater secular growth and qualification-based captivity than general compressors. Q2 suggests this is no longer only a margin-repair story; orders are growing faster than the group.

Industrial recovery. A sustained manufacturing and project-capex upturn would restore positive ITS volume. Given the fixed-cost base, the bull case expects incremental adjusted EBITDA margins above 30%. Q2 failed that conversion, but price actions and productivity are supposed to improve the second half. This is the nearest dated catalyst.

Power, semiconductors, and data infrastructure. Compressors support power generation and air separation; pumps and blowers support water and closed-loop systems; odorization supports natural-gas infrastructure. These markets can grow faster than general industrial, but theme exposure should be measured in actual orders, not narrative. IR does not disclose data-center revenue, so no pure-play premium is warranted.

M&A. Closed acquisitions contribute 2.5 percentage points to 2026 revenue guidance. Eleven LOIs and a 200-company funnel support continued deployment. The revenue is highly visible; the value created is not. Growth through M&A deserves credit only when incremental NOPAT exceeds the acquired capital including goodwill.

Growth verdict: the quality improved from low to mixed. Q2 establishes a plausible organic inflection and P&ST strength, but two consecutive negative-volume years cannot be erased by one shipment quarter. A high-quality verdict requires orders, margins, cash, and ROIC to follow.

6. Financial Quality

Multi-year summary

Sources: filing-reconciled IR Forms 10-K for 2021–2025, especially the FY2025 10-K, and the Q2-2026 10-Q. TTM equals FY2025 less H1-2025 plus H1-2026. The TTM GAAP rebound largely reflects the Q2-2025 impairment rolling out of the window, not comparable organic earnings growth.

The margin record is excellent. Gross margin expanded more than eight points from 2020 to 2025 and operating margin almost tripled. IRX, price, merger synergies, portfolio pruning, sourcing, and acquisition integration all contributed. The model is capital-light: H1 capex was $63 million, 1.6% of revenue. Working capital is the larger short-term cash swing because inventory and receivables build ahead of backlog conversion.

Q2 also shows why peak margins should not be assumed permanent. Gross margin fell from 43.7% to 42.1%; adjusted EBITDA margin from 27.0% to 25.4%. ITS suffered China inflation/price pressure and growth spending, while corporate costs increased to $49.1 million from $34.6 million, partly an incentive true-up. P&ST offset some of this with a 200-basis-point margin expansion. The divergence supports a portfolio view: P&ST economics are improving while the large ITS core remains regionally price-sensitive.

Cash conversion and earnings quality

IR defines FCF conservatively as operating cash flow less capex. FY2025 FCF of roughly $1.22 billion materially exceeded GAAP net income because acquired-intangible amortization and impairment are noncash. That is real cash quality, but the add-backs are not economically irrelevant. Acquisition-related amortization is recurring so long as acquisitions continue; it represents the accounting consumption of purchased customer relationships and technology. Adjusted EPS is useful for operating comparison but a ceiling on owner earnings, not a substitute for deal returns.

First-half 2026 was weak on cash conversion. Operating cash flow fell to $495.6 million from $502.1 million and FCF was flat at $432.3 million, while revenue rose 8.1% and adjusted net income rose 4.2%. Inventory consumed $76.7 million; accounts payable used $68.3 million; other assets/liabilities used $100.0 million. Q2 alone improved sharply, but H1 is the better seasonal comparison. The initial $25 million ILC Dover insurance receipt also helped Q2 cash and does not represent operating earnings.

Balance sheet

At June 30, cash was $1.174 billion and total debt $4.769 billion, for net debt about $3.60 billion. Net leverage was 1.7x adjusted EBITDA. Liquidity was $3.8 billion, including $2.6 billion of undrawn revolver capacity; Moody’s upgraded IR one notch to Baa1 in June. Maturities are manageable and the company retains meaningful acquisition capacity.

The apparent conservatism requires an intangible overlay. Goodwill was $8.542 billion and other intangibles $4.072 billion, versus common equity of $10.177 billion. Tangible common equity was therefore approximately negative $2.44 billion. Book value is not an asset floor, and the headline ROE is not an economically clean quality measure. The relevant balance-sheet risks are overpayment, impairment, and leverage after a future large deal—not near-term solvency.

Return on capital

A transparent full-capital calculation uses NOPAT divided by average common equity plus debt less cash. TTM GAAP operating income was $1.436 billion. Removing the $25 million ILC insurance receipt and $10.3 million tariff refund, then applying a normalized 22% tax rate, produces NOPAT of approximately $1.09 billion. Average invested capital was about $13.70 billion, yielding approximately 8.0%. Precise results vary with treatment of impairment, leases, and excess cash, but no reasonable method produces a sustained 15% corporate ROIC. Computed third-party fields are treated cautiously because their definitions vary; filing-reproducible math governs.

The EPV/asset-value relationship tells the same story. Market EV is far above reproduction book value because the installed base, brands, service organization, and IRX capability have genuine franchise value. Yet EPV on sustainable NOPAT at a 9–10% capital charge is below the current EV unless one normalizes material amortization and credits continued growth. The market is not paying only for current earnings power; it is paying for reinvestment.

Financial-quality verdict: strong margins, low capex, ample liquidity, and historically good cash conversion; weak corporate-level returns once goodwill is included. Q2 demand improved before profitability and H1 cash did, making second-half conversion the critical test.

7. Capital Allocation

IR’s capital-allocation record contains both a compelling process and a mediocre aggregate output. From 2021 through 2025, acquisition spending totaled approximately $5.7 billion. Most transactions were small bolt-ons in compression, vacuum, pumps, and flow control. These deals can use existing channels, service networks, sourcing, and IRX tools; cost synergies are more credible than revenue synergies. The company often cites low-double-digit or single-digit pre-synergy multiples, then improves margins after closing.

ILC Dover is the exception that matters. IR paid about $2.35 billion in 2024 to enter biopharma single-use and aerospace/defense. In Q2-2025 it recorded $170.3 million of Biopharma goodwill impairment, $59.4 million of Aerospace & Defense goodwill impairment, and $36.1 million of tradename impairment: $265.8 million attributable to ILC Dover. A separate $120.9 million impairment related to the HPS equity-method investment in the same quarter and must not be mislabeled as ILC. The combined $386.7 million of observed charges still made the quarter a severe capital-allocation event, but only the first $265.8 million was an ILC goodwill/intangible write-down. The episode proved that moving outside familiar bolt-on terrain can destroy value quickly.

The Q2-2026 insurance recovery is meaningful but should be framed correctly. IR reached an initial $187.5 million settlement under representations-and-warranties insurance, collected $25 million in Q2, expects $162.5 million more during 2026, and is pursuing additional recovery. It excludes proceeds from adjusted earnings and FCF guidance. Cash loss is therefore lower than the impairment implied. But insurance reimburses a breached representation; it does not demonstrate that the remaining acquired assets earn the purchase price or that diligence was adequate.

Prospective behavior was encouraging. IR closed Lone Star Blowers, adding about $50 million of annual revenue plus service/rental aftermarket, and signed Fai Filtri, adding about $30 million and filter aftermarket. Management described both as low-double-digit pre-synergy bolt-ons. It also said it walked away from one approximately $1 billion purchase-price opportunity because valuation failed its standard. Walking away is one of the cleanest observable signals of discipline in a competitive M&A market.

Returns to shareholders are secondary. H1-2026 repurchases were $339 million, including $240 million in Q2, and dividends were $15.7 million. The dividend remains token at about $0.08 per share annually. Buybacks reduced adjusted diluted shares from 404.9 million to 391.7 million year over year, making EPS growth exceed net-income growth. The 2025 $1.0 billion buyback was executed near historically high prices; 2026 repurchases are occurring at a lower valuation and are therefore better timed.

Incentives remain the structural weakness. The annual plan uses adjusted EPS and FCF; performance shares rely heavily on relative TSR and adjusted-EPS CAGR. There is no disclosed ROIC, economic-profit, or acquisition-IRR hurdle in the 2026 proxy. EPS can rise when a low-return acquisition is funded cheaply or when shares are repurchased, even if intrinsic value per dollar retained does not. The all-employee Ownership Works equity culture is a genuine positive, but it does not solve the executive metric mismatch.

Insider evidence has turned modestly positive. Director Aurobind Satpathy bought 11,538 shares in the open market on 2026-08-03 at a weighted-average $86.678, an approximately $1.00 million purchase that was not made under a 10b5-1 plan. These were his first directly owned shares and the only code-P purchase in the mirrored 2026 Form 4 corpus (Form 4, filed 2026-08-05). Other post-baseline filings were routine option exercises, administrative dispositions, and tax withholding, with no code-S open-market sales. One director purchase is not a cluster and cannot prove value, but it directly falsifies the prior report’s statement that no insider bought through the de-rate.

Capital-allocation verdict: upgraded from weak to mixed, not to strong. The insurance recovery, bolt-on focus, lower-priced buybacks, and $1 billion deal walkaway are positive. All-in ROIC near WACC, the ILC Dover failure, and compensation without a return hurdle remain the governing evidence.

8. Changes and Headwinds — Last Two Years

The analytical stance is less negative at the margin. Demand evidence improved and capital-allocation behavior became more disciplined. The reason not to upgrade the quality verdict is equally concrete: higher volume has not yet produced higher margins, cash, or returns on capital. That gap is now the central monitorable.

The last two years transformed the thesis along four axes. First, ILC Dover expanded P&ST and then produced a rapid impairment, making acquisition discipline observable rather than theoretical. Second, organic volume declined in 2024–2025 even as reported revenue and margins rose, exposing dependence on price and acquisitions. Third, tariffs and China overcapacity created a local price/cost headwind in 2026. Fourth, Q2-2026 finally produced broad organic revenue growth, with P&ST orders and margins especially strong.

The operating environment remains mixed. North American compressors showed high-single-digit orders in Q2; Europe had delayed blower/vacuum projects; the Middle East remained delayed; China demand improved but price lagged inflation. Management’s July update suggests project timing is clearing, but no cancellation disclosure means backlog quality must be inferred from eventual conversion.

Capital deployment also shifted. The 2024 platform bet gave way to 2025–2026 bolt-ons. The company has ample dry powder, 11 LOIs, and a large funnel. This makes the decision to walk away from a billion-dollar target important, but the risk cannot be retired: the balance sheet can support another large deal and executive pay still rewards adjusted-EPS growth.

Guidance embeds a demanding second half without raising the headline EBITDA range. Full-year revenue is expected to grow 4.5–6.5%, yet $2.13–2.19 billion of adjusted EBITDA implies margin below 2025. Management expects first-half pricing, productivity projects, restructuring, and normalized corporate costs to improve H2. If that bridge fails, the organic recovery will have revealed weaker pricing power and operating leverage than the premium-industrial narrative assumes.

Changes verdict: modestly thesis-strengthening on demand and process discipline, thesis-weakening on near-term conversion. The update reduces recession risk but does not resolve returns.

8A. Management Quality, Incentives, and Ownership

Vicente Reynal deserves substantial operating credit. Since the 2020 combination, management simplified the portfolio, installed IRX across a much larger enterprise, expanded gross margin by more than eight points, raised segment profitability into the high 20s, maintained low capex, and built an acquisition-sourcing system with repeatable integration tools. These are difficult accomplishments. The evidence is not only presentation material: it appears in filing-reconciled gross profit, segment margins, working-capital processes, and the speed with which acquired companies adopt common pricing and productivity disciplines.

The harder judgment is capital allocation. Management often discusses acquisitions in terms of strategic fit, aftermarket content, pre-synergy purchase multiples, and post-integration margin expansion. Those are useful inputs but not a shareholder-return scoreboard. An asset purchased at 12x EBITDA can become a 9x synergy-adjusted asset without creating value if the cost of integration, time, taxes, and goodwill consume the spread. The appropriate management assessment is therefore split: high confidence in operational capability, medium confidence in bolt-on selection, and low-to-medium confidence in large-platform underwriting after ILC Dover.

The ILC episode should be neither exaggerated nor minimized. The filing attributes $265.8 million of goodwill and tradename impairment to ILC and separately records a $120.9 million HPS equity-method impairment. The subsequent $187.5 million insurance agreement indicates that representations-and-warranties protection had real value and that management pursued recovery effectively. It also indicates that information supplied in the transaction was serious enough to support a large claim. Recovering cash is good stewardship after the fact; it does not establish that the initial diligence and purchase price met the required standard.

Prospective conduct in 2026 is more encouraging. Walking away from an approximately $1 billion opportunity because price exceeded the company’s standard is stronger evidence than a generic claim of discipline. Lone Star Blowers and Fai Filtri fit the installed-base and aftermarket logic more closely than a platform leap. Q2 repurchases at an average $71.13 were also more sensible than approximately $1.0 billion of 2025 buybacks near an estimated $86 average. These choices suggest management is responding to the lessons embedded in the de-rating.

Compensation

The proxy does not fully align with the economic problem. The annual corporate incentive is 75% adjusted EPS and 25% FCF. Long-term awards are 50% relative-TSR performance shares, 25% time-vesting restricted stock, and 25% options. The older special option award uses adjusted-EPS CAGR and a stock-price/TSR hurdle. None of the disclosed programs uses goodwill-inclusive ROIC, economic profit, or a deal-vintage return test.

There is some genuine downside discipline. The 2025 annual plan paid only 69% of target because adjusted EPS and FCF missed their targets, and the fourth 100,000-option tranche under the special award was forfeited when 2% adjusted-EPS growth missed a 12% hurdle. Relative-TSR awards are capped at target when absolute TSR is negative. Those provisions prevent compensation from being a one-way ratchet. They do not address the core loophole: adjusted EPS can rise through leverage, acquisition amortization add-backs, or buybacks even when returns on incremental capital remain below WACC.

CEO 2025 reported compensation was $16.2 million, or 215 times the median employee, including the special option tranche. Size alone does not determine alignment; the more relevant question is what the package asks management to optimize. A serial acquirer should be paid partly on multi-year economic profit or post-integration ROIC. Until the board adds such a metric, shareholders must assume that growth and per-share earnings will receive more weight than capital efficiency.

Ownership signals

Insider data improved after the prior report. Aurobind Satpathy, appointed to the board in 2025, purchased 11,538 shares on the open market for approximately $1.00 million on August 3, 2026, at $86.678 per share. The trade was not identified as a 10b5-1 transaction and represented his first direct ownership. It is the only code-P purchase in the mirrored 2026 Form 4 corpus, while subsequent and other baseline-period filings were grants, exercises, withholding, or administrative dispositions rather than open-market sales.

The signal should be calibrated. A $1 million director purchase is economically meaningful and occurred above the report’s $78.57 reference price, so it is more informative than a token grant. It also falsifies the previous assertion that no insider bought during the de-rating. But a single outside director does not have the same information content as coordinated CEO/CFO purchases, and there is no cluster. It moves the ownership evidence from negative to modestly positive, not strongly bullish.

Management also promotes broad employee ownership through the Ownership Works program. Cultural alignment can improve retention, continuous improvement, and attention to working capital. It is not a substitute for a board-level return metric. Employee equity rewards execution inside the business; ROIC-linked compensation would govern the price paid to add new businesses.

Management verdict: elite operating execution, improving evidence of price discipline, and a modestly better ownership signal. The unresolved weakness is board-level incentive design for a serial acquirer whose main valuation debate is capital efficiency.

9. Risk Matrix and Falsification Tests

The central risk is not ordinary industrial cyclicality. IR has enough aftermarket, geographic breadth, and balance-sheet capacity to endure a normal recession. The central risk is paying a quality multiple for a serial acquirer whose consolidated reinvestment return has not exceeded its cost of capital. Cyclicality matters because a downturn can expose that gap, but capital allocation determines whether the gap persists after demand recovers.

Demand falsification

The bull case previously required organic growth above 3%, not merely reported growth purchased through M&A. Q2 crossed that hurdle at 4.1%, but only once. The more forward-looking order signal was much weaker: 1.6% consolidated and 0.1% in ITS. Management’s July update is encouraging because delayed long-cycle work closed across power, air separation, pharma, food and beverage, and semiconductors. It is not sufficient because management itself warned that the double-digit rate should not be extrapolated.

The appropriate demand test is two-dimensional. First, organic orders should remain at least in line with the 1–3% full-year organic revenue guide after July timing normalizes. Second, ITS book-to-bill and backlog conversion should improve without requiring more inventory as a percentage of sales. Failure on both would show that Q2 was a shipment event. Passing both would establish the first sustained organic recovery since the negative-volume years.

The peer cross-read raises the standard. Atlas Copco’s Compressor Technique posted 19% organic order growth in Q2 while IR’s ITS organic orders were nearly flat; AMETEK and IDEX also reported broad order acceleration. Definitions, geography, and project timing differ too much to infer a precise share loss. Still, a strong market cannot be used as an excuse for weak relative orders. If the divergence persists for another two quarters, the burden shifts to management to explain share, portfolio, or execution.

Margin falsification

The Q2 debate is unusually clean. Revenue was not the problem; conversion was. Adjusted EBITDA increased $10.6 million while revenue increased $160 million. Acquisitions and FX contributed more than the total first-half EBITDA increase, while organic gross profit declined. In ITS, organic revenue grew but organic gross profit fell. That is incompatible with the high-incremental-margin bull case unless the pressure is demonstrably temporary.

Management identifies three reversals: China price/cost actions, productivity and restructuring, and normalization of corporate incentive expense. Those are dated claims. H2 consolidated incremental margin should therefore exceed the first half materially, ITS margin should move back toward its prior high-20s level, and P&ST should retain a margin near or above 30%. If revenue grows but adjusted EBITDA guidance remains unchanged or is cut, IRX will have failed its most important near-term test.

Cash and return falsification

Headline H1 FCF of $432.3 million was flat, but it included a $25 million insurance receipt. Excluding that item, underlying FCF was approximately $407 million, down about 6%. Operating working capital rose $166 million from year-end, and inventory excluding LIFO increased $72 million while accounts payable fell $85 million. Some build may be rational if it supports access to channels and converts backlog. It becomes evidence against earnings quality if the build persists after revenue has accelerated.

The decisive long-term test remains full-capital ROIC. A sustainable move through 10% would indicate that organic recovery, IRX improvement, and bolt-on discipline are finally producing value above a reasonable capital charge. A return stuck near 8% would mean the operating franchises remain attractive but purchase premiums continue to absorb their rents. This test must include goodwill and acquired intangibles. Excluding them answers whether the factories are good; including them answers whether shareholders received good returns on the checks written.

10. Valuation and Embedded Expectations

Current enterprise value

At the August 25 close of $78.57 and 387.995 million quarter-end shares, market capitalization is approximately $30.49 billion. Adding $4.83 billion of debt and $65.7 million of noncontrolling interest and subtracting $1.17 billion of cash gives a live enterprise value of approximately $34.21 billion. This hand-rebuilt value uses the current price; the third-party period-end EV is higher because it marks equity at a stale quarter price.

The reported and adjusted denominators tell different stories. Against TTM reported EBITDA of approximately $1.97 billion, current EV is 17.4x. Against approximately $2.12 billion of trailing adjusted EBITDA, it is about 16.2x. The stock trades at 4.3x TTM sales and about 22.0x the high end of 2026 adjusted EPS guidance. GAAP P/E is above 32x, but the comparison is distorted by acquisition amortization and by the Q2-2025 impairment rolling out of the trailing window. None of these measures alone is dispositive; together they show a premium industrial valuation, not distress.

AZI’s own-history composite is 39.6th percentile, with P/E at 25.4, P/B at 45.4, and P/S at 47.9. That is a sharp apparent de-rating from the June report’s 63rd percentile. The change is directionally useful but mechanically imperfect. The P/E denominator improved when a large impairment rolled out, and P/B provides no tangible downside floor because tangible common equity is negative. P/S and EV/EBITDA are cleaner continuity checks; both suggest the stock is below its recent enthusiasm but above ordinary-industrial valuation.

Peer framework

Current peer EV/EBITDA spans roughly 15.9x at Dover to the low-to-mid 20s for AMETEK, Nordson, and Parker-Hannifin. A six-company comparison produces a median near 21.1x, leaving IR at an apparent discount. That discount should not be closed mechanically. AMETEK and Parker earn materially higher full-capital returns; Nordson has attractive precision exposure; Roper has a much larger recurring-software mix; Atlas Copco’s compression franchise generates far higher returns. Dover is the better lower-bound comparison because it combines industrial cyclicality, niche platforms, and M&A.

IR deserves some premium to an average machinery company for its aftermarket, low capex, IRX record, and P&ST margin trajectory. It deserves a discount to the best compounders until its ROIC and organic conversion converge with theirs. The current multiple sits near that uneasy middle: not enough to call the stock expensive on a peer screen, but too high to ignore the return gap.

Reproduction value and earnings power

The balance sheet cannot provide a conventional asset floor. Common equity was $10.18 billion, but goodwill and acquired intangibles were $12.61 billion, leaving tangible common equity negative. A hard tangible operating reproduction calculation—current assets less non-debt current liabilities plus net PP&E—is only about $3.3 billion before assigning value to brands, installed base, distribution, technicians, certifications, and customer relationships. Those intangibles are economically valuable, but disclosure does not permit a precise replacement-cost estimate.

Earnings Power Value is more informative. Sustainable unlevered cash earnings can be normalized around $1.35–$1.50 billion using operating cash flow, after-tax interest, and maintenance capex while excluding insurance proceeds. Capitalizing that stream at an 8.5–9.5% cost of capital with zero real growth gives enterprise EPV of approximately $14.2–$17.6 billion. Current EV is 1.9–2.4 times that range. The point is not that IR should trade at EPV: its installed-base franchise and reinvestment opportunity plainly deserve growth value. The point is that a large portion of the quoted value depends on successful reinvestment rather than today’s no-growth economics.

Reverse expectations

A simple reverse DCF using $34.2 billion of EV, $1.4–$1.5 billion of normalized starting FCFF, a 2.5% terminal growth rate, and an 8.5–9.5% discount rate requires approximately 7–9% FCFF growth for a decade. That is well above the 1–3% organic revenue guide. The bridge must come from margin recovery, bolt-on acquisitions, share gains, working-capital normalization, and continued capital deployment.

The load-bearing assumption is therefore not simply an industrial recovery. It is that IR can recycle more than $1 billion of annual cash into niche assets at returns above WACC while avoiding another platform error. If organic growth settles at 2% and acquisition returns remain near 8%, the reverse-DCF path is difficult even if adjusted EPS compounds faster through buybacks. If P&ST keeps scaling, ITS margins recover, and bolt-ons earn double-digit post-integration returns, the path becomes plausible.

Scenario framework

These scenarios are analytical ranges, not price targets or recommendations.

The bear case is not a recession case; it is a mature-growth case in which the current acquisition system adds revenue but not economic profit. The base case broadly matches management’s long-term algorithm and assumes no further platform mistake. The bull case requires proof unavailable today: sustained orders, high incrementals, and consolidated returns above WACC. At the current EV, the market gives IR meaningful credit for the base case and some probability of the bull case. There is little asset or EPV protection if the bear case becomes the normalized outcome.

Valuation verdict: below peak enthusiasm and below premium peers, but still dependent on value-creating reinvestment. The stock is fairly valued for improving execution, not cheap against current earnings power.

11. Variant View and Market Positioning

The consensus-friendly narrative says IR is a quality industrial compounder: high aftermarket, an elite operating system, low capex, ample M&A runway, secular exposure to power and life science, and consistent adjusted-EPS growth. Nearly every statement is individually true. The variant is that the corporate economics are weaker than the operating narrative because acquisition premiums absorb the franchise value. IR can expand margins dramatically and still fail to earn an excess return on the capital employed.

The bearish variant is too simple in the other direction. Calling IR only an overvalued roll-up ignores real installed-base captivity, the scale of IRX improvement, better P&ST economics, an investment-grade balance sheet, and new evidence of price discipline. The $187.5 million insurance recovery and the decision to abandon a billion-dollar target are not cosmetic. They reduce the probability that the 2024 platform mistake repeats immediately. Director Satpathy’s $1 million open-market purchase at a price above the current quote adds a modest, independent signal that value may be emerging.

The investable variant is narrower: organic demand has inflected before economic returns have. That creates an asymmetric information window. If H2 margins and cash follow Q2 revenue, estimates can rise while the valuation remains below the premium cohort. If they do not, the unchanged EBITDA guide will prove more informative than the raised revenue guide, and the stock can de-rate toward mature-acquirer economics.

Factor data support this show-me framing. IR is below its 50- and 200-day EMAs, has fallen about 17% in six months, and is roughly flat over one year. Yet it has rebounded from the May low and is not statistically washed out. Its factor model is dominated by market beta, Industrials, and Industrial Automation; Momentum, Value, and Growth are zeroed rather than dominant. Approximately 65.5% of variation is factor-explained and idiosyncratic volatility is still about 22.8%. Investors are buying a cyclical quality-industrial outcome, not a hidden low-volatility bond proxy.

The five-year risk-adjusted record is also sobering. Annualized return is roughly 9.4% with volatility above 30%, a maximum drawdown near 37%, and a Sharpe ratio around 0.24. That realized path is inconsistent with the smooth-compounder label even though operating margins improved. A rerating to the AMETEK/Parker tier requires not just a better quarter but a better relationship between growth, capital, and drawdowns.

Why the market may be wrong

The market may be too skeptical if Q2 is the start of a broad order cycle and first-half margin pressure is genuinely transitory. P&ST already demonstrates the operating leverage the consolidated bull case requires. A normalized corporate-cost line, better China price recovery, and backlog conversion could produce a sharp H2 incremental margin. At the same time, buybacks at lower prices reduce the share count, and bolt-ons add aftermarket. Under that combination, adjusted EPS and owner cash could grow faster than the 1–3% organic guide implies.

The market may still be too optimistic if it treats adjusted EBITDA growth as value creation without charging for acquisitions. H1 reported revenue growth was 8.1%, but only 2.0% was organic; acquisitions and FX supplied three-quarters of the increase. If buyers bid up niche-industrial assets because every compounder wants them, IRX synergies may accrue to sellers. A large funnel and 11 LOIs increase deployment visibility and reinvestment risk at the same time.

Variant verdict: neither the compounder label nor the roll-up critique is sufficient. The differentiated stance is to underwrite the operating system but withhold a premium corporate multiple until full-capital returns confirm value creation.

12. Facts, Interpretations, and Open Questions

The most consequential missing disclosure is deal-level return data. IR provides revenue, margin-improvement stories, purchase-price allocation, and adjusted accretion, but not vintage invested capital, post-integration NOPAT, or realized cash-on-cash return. Without those data, consolidated ROIC is the only defensible scoreboard, even though it lags current deal quality and mixes the 2020 transaction with subsequent bolt-ons.

Market share is the second major gap. Management-estimated rankings and TAM do not establish stability. IR does not publish an installed-base count, product-level share series, aftermarket attach rate, renewal rate, or service retention. Atlas Copco’s Q2 order gap is adverse evidence but not proof. A reliable share conclusion would require consistent product and geography definitions across several periods.

The third gap is organic composition. The filing bridges organic growth but does not quantify price versus volume for Q2. Management’s China comments imply local price/cost pressure and North American price of 1–2%, yet no consolidated split is disclosed. That matters because volume typically carries better incremental economics than price recapture. Until the split and gross-profit bridge improve, 4.1% organic revenue is a positive but incomplete quality signal.

13. What Must Be True

For the current enterprise value to be justified without relying on multiple expansion, five propositions must hold.

1. Organic growth must normalize above the mature-market floor. The 1–3% 2026 guide cannot be a temporary recovery before another zero-growth period. ITS orders must confirm Q2 revenue, while P&ST should sustain mid-single-digit or better growth.

2. IRX must restore incremental economics. Consolidated adjusted EBITDA should grow at least as fast as revenue once Q2’s China, investment, and corporate-cost headwinds normalize. A 30% or better incremental margin over a multi-quarter period would validate the operating leverage embedded in the premium narrative.

3. Cash must follow earnings without insurance help. H2 working capital should release, underlying FCF should grow, and conversion should move back toward management’s 95% objective. Inventory can lead sales temporarily; it cannot remain a permanent use of cash.

4. Marginal acquisitions must clear WACC after goodwill. Bolt-ons need to generate post-integration NOPAT returns above 10%, not merely adjusted-EPS accretion. A continued walkaway discipline is as important as deployment volume in a crowded acquisition market.

5. Governance must evolve toward capital efficiency. A future proxy should include ROIC, economic profit, or a return-based acquisition hurdle. Until then, investors must police the difference between adjusted EPS growth and value creation themselves.

The observable upgrade path is equally clear: two consecutive quarters with organic orders and revenue above 3%, consolidated incremental adjusted EBITDA margin above 30%, underlying FCF growth, and full-capital ROIC moving through 9–10%. The downgrade path is zero-or-negative organic orders, failure of the H2 margin bridge, renewed working-capital absorption, or a large platform acquisition priced on synergy-adjusted accretion rather than stand-alone return.

Catalyst and monitoring calendar

The next quarterly release is the most important near-term catalyst because it will contain all four validation signals in one place. Orders will show whether July’s delayed projects represented a durable change in demand. Segment margins will test the promised China price/productivity and corporate-cost normalization. The cash-flow statement will show whether inventory and payables reverse. Recognition of the remaining $162.5 million insurance recovery must be separated from operating cash and adjusted results when assessing conversion.

The following quarter matters more for falsification than for the initial reaction. Two successive order prints are necessary to distinguish a cycle from timing; two margin bridges are necessary to determine whether IRX is restoring incremental economics. Investors should calculate both reported FCF and FCF excluding insurance or other one-time receipts. They should also rebuild average invested capital after every material acquisition rather than accepting adjusted-EPS accretion as a proxy.

Annual proxy disclosure is a slower but important catalyst. The highest-quality governance improvement would be an explicit goodwill-inclusive ROIC or economic-profit component in long-term compensation. Less decisive changes—larger stock ownership requirements or more options—would increase equity sensitivity without necessarily improving acquisition discipline. Future Form 4 filings should be watched for follow-on open-market purchases by the CEO, CFO, or other directors; grants and tax withholding should not be counted as discretionary conviction.

M&A announcements will likely dominate interim news. Each should be screened through four questions: stand-alone purchase multiple before synergies, amount assigned to goodwill/intangibles, strategic overlap with existing service density, and a credible path to post-tax return above 10%. A small transaction can destroy value if auction pricing is high; a larger transaction can create value if the target brings genuine captivity and the price leaves IRX upside to the buyer. The current evidence favors familiar aftermarket bolt-ons and argues for skepticism toward another platform adjacency.

Finally, peer releases provide a useful control group. Atlas Copco Compressor Technique is the closest demand and share cross-read; AMETEK, IDEX, Dover, and Parker test whether premium industrial orders and margins are broadly strengthening. IR does not need to match any single peer quarter, but a persistent ITS order gap during a broad industrial upswing would turn today’s caution into stronger evidence of lost momentum.

14. Final Institutional Synthesis

IR is better than the June thesis implied on near-term demand and process discipline. The Q2 organic rebound was real, P&ST delivered both orders and margin, management raised revenue guidance, insurance reduced the ILC cash damage, a billion-dollar deal was rejected, buybacks were executed at lower prices, and a director purchased $1 million of stock in the open market. Those changes weaken the bear case.

They do not complete the bull case. ITS orders barely grew, adjusted EBITDA lagged revenue, underlying H1 FCF declined, and all-in ROIC remains around 8%. The company still funds growth primarily through a combination of bolt-ons and a high-quality operating system operating in a competitive auction market. The physical businesses are capital-light; the corporate growth model is capital-hungry because goodwill is its principal productive asset.

That distinction reconciles the apparently contradictory evidence. IR can be an excellent operator, possess real customer captivity, and improve acquired margins while delivering only WACC-level corporate returns. It can also improve those returns if the current bolt-on discipline, P&ST scaling, and organic recovery persist. The stock at $78.57 prices meaningful progress but no longer assumes a perfect premium-compounder outcome.

Institutional conclusion: the thesis is improving but unproven. Demand has passed the first test; margins, cash, and capital returns have not. The next two quarters should be judged less by reported revenue and adjusted EPS than by ITS organic orders, incremental EBITDA, underlying FCF, and goodwill-inclusive ROIC.

APPENDIX A — Standard Diligence Questionnaire

General

What thoughtful questions have other investors asked about this company?

The recurring questions are: Is IRX a durable operating advantage or a transferable management toolkit? Can consolidated ROIC rise above WACC after including goodwill? Is aftermarket genuinely recurring, or merely less cyclical point-in-time product revenue? Did negative organic volume in 2024–2025 reflect the cycle, share loss, or portfolio mix? Can P&ST sustain low-30s margins? Will China price/cost pressure reverse? Does the ILC Dover insurance recovery materially repair the capital-allocation record? Can management deploy more than $1 billion of annual cash without overpaying in a crowded niche-industrial acquisition market? Why does executive compensation omit ROIC? What does director Aurobind Satpathy’s $1 million purchase signal?

Interpretation: These questions converge on one issue: whether excellent operating execution produces excess shareholder returns after acquisition cost. Q2-2026 improved the demand and discipline evidence but did not settle margin conversion, cash conversion, or full-capital ROIC.

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Are they driven by the external environment or company-led actions?

IR is not at an obvious earnings trough. TTM revenue is a record $7.94 billion and 2026 adjusted EBITDA guidance of $2.13–$2.19 billion is near the 2025 record. Margins have eased from peak levels: Q2 adjusted EBITDA margin was 25.4%, down 160 basis points, versus 27.4% for FY2025. General industrial demand is recovering unevenly, while China price/cost and prior corporate-cost items depress current conversion.

Company-led actions drove much of the five-year improvement. IRX, pricing, sourcing, merger synergies, restructuring, portfolio management, and acquisitions lifted gross margin from 38.6% in 2021 to 43.6% in 2025. External inflation initially helped price; the 2024–2025 slowdown hurt organic volume; FX and M&A supplied most H1-2026 reported growth. The current earnings level therefore combines structural company-led improvement with a not-yet-complete cyclical recovery.

How stable are revenues, and what is the outlook for products and services?

Revenue is moderately cyclical. Original equipment depends on industrial production and project capex; aftermarket depends more on utilization and uptime. Q2 aftermarket was 35.9% of consolidated sales, giving the company a stabilizer but not a subscription profile. Only 9.8% of Q2 revenue was recognized over time.

The near-term outlook is improving. Management guides to 4.5–6.5% reported revenue growth in 2026, including 1–3% organic, 2.5% M&A, and 1% FX. Q2 organic revenue was 4.1%, but orders were only 1.6%; ITS orders were nearly flat while P&ST orders rose 7.4%. July orders were double digit partly because delayed long-cycle projects closed. The outlook is positive but requires confirmation after timing normalizes.

How big will the market be? Is it growing, shrinking, domestic, or international?

Management has cited approximately $40 billion of ITS addressable market at the 2023 Investor Day and a later $67 billion portfolio TAM after acquired and targeted adjacencies. These are management estimates, not audited market-size series. The underlying compressor, vacuum, blower, and precision-flow markets are global and generally grow at low-to-mid single-digit rates, with faster pockets in power, semiconductors, water, life science, and infrastructure.

IR is internationally diversified. North America is important, but Europe, the Middle East, China, and the rest of Asia matter to both growth and price/cost. China is approximately 10% of sales and currently shows low-double-digit organic revenue but unfavorable original-equipment mix and pricing.

Business Quality & Competitive Moat

Is the industry getting more or less competitive?

Original-equipment competition remains active among Atlas Copco, IR, Kaeser, Hitachi/Sullair, Elgi, Kaishan, Busch, Pfeiffer, IDEX, Dover, Graco, and many regional specialists. China shows a localized adverse capacity cycle. The more important competitive escalation is in acquisitions: public compounders, private equity, and strategics bid for the same high-margin niche assets. IR’s decision to walk away from an approximately $1 billion target is favorable evidence, but its 11 LOIs and 200-company funnel show deployment competition remains intense.

How profitable are the business and the industry?

Operating profitability is high. ITS and P&ST Q2 adjusted EBITDA margins were 26.8% and 31.5%. Gross margin rose more than eight points from 2020 to 2025. Full-capital profitability is much lower: filing-rebuilt TTM ROIC is approximately 8.0% after including goodwill, compared with an estimated 9–10% WACC. Peer ROIC is generally higher: Atlas Copco’s Compressor Technique has exceptionally high returns, while AMETEK and Parker-Hannifin also exceed IR on consolidated measures.

What barriers to entry exist? Do brands matter? What are customers’ switching costs?

The main barrier is customer captivity after installation. Compatible parts, known technicians, service density, configured equipment, validated processes, and uptime risk raise search and switching costs. Brands matter as shorthand for installed-base compatibility and reliability, not primarily through consumer advertising. Barriers are strongest in aftermarket, life-science validation, safety-critical systems, and engineered applications. New-equipment bids remain contestable, so the moat is narrow and product/locality-specific rather than corporate-wide.

Can the business be easily understood, and can it be undermined by foreign low-cost labor?

The operating model is understandable: sell engineered equipment, then service the installed base; acquire niche assets and improve them through IRX. Portfolio breadth and acquisition accounting complicate consolidated analysis. Low-cost manufacturing can pressure commodity components and new equipment, particularly in China, but it does not easily reproduce a qualified application, local service network, installed base, or uptime reputation. The risk is price pressure and share erosion in less differentiated hardware, not wholesale labor arbitrage of the service franchise.

Financial Condition & Balance Sheet

Are assets not fully recognized on the balance sheet?

Yes. The installed base, local technician density, customer relationships, distributor network, IRX operating routines, and product reputation have economic value not fully captured in tangible assets. Conversely, the balance sheet recognizes $12.61 billion of goodwill and acquired intangibles, making tangible common equity approximately negative $2.44 billion. Book value is therefore neither a clean asset floor nor a direct measure of organically created franchise value.

Are there off-balance-sheet liabilities, and how conservative is the accounting?

Ordinary leases, warranties, restructuring obligations, environmental matters, litigation, and acquisition contingencies exist, but no disclosed item threatens solvency. The more important analytical liability is continuing acquisition dependence: adjusted measures exclude recurring acquired-intangible amortization and certain transaction costs. Those adjustments are useful for operating comparison but can overstate owner economics if acquisition spending is perpetual. The report therefore emphasizes GAAP cash flow and goodwill-inclusive ROIC.

How capex-hungry is the business?

It is not physically capex-hungry. H1-2026 capex was $63.3 million against $59.6 million of depreciation excluding acquired-intangible amortization, and only 1.6% of revenue. Acquisition capital is much larger and economically functions as growth capex. Through June, 2026 acquisition consideration was $163.2 million, 97.4% of which was provisionally allocated to goodwill and other intangibles.

How strong is liquidity?

At June 30, IR held $1.17 billion of cash, $4.77 billion of debt, and approximately $3.8 billion of total liquidity. Net leverage was 1.7x adjusted EBITDA. Current debt of $699.8 million is mainly 2027 notes reclassified within one year, and cash covers it about 1.7x. Moody’s upgraded the company to Baa1. Catastrophic balance-sheet risk is low absent a very large leveraged transaction.

Capital Allocation & Management

How much FCF does the business generate, and how does management use it?

FCF was $1.27 billion in 2023, $1.25 billion in 2024, $1.22 billion in 2025, and approximately $1.22 billion TTM. H1-2026 FCF was $432.3 million, but included a $25 million insurance receipt; underlying FCF declined about 6%. Management prioritizes acquisitions, then buybacks, with a token dividend. H1 repurchases were $338.8 million and dividends $15.7 million.

What is management’s capital-allocation philosophy?

Management seeks niche assets with aftermarket, low-double-digit or lower pre-synergy multiples, strategic adjacency, and IRX margin opportunity. The philosophy is coherent and repeatable for bolt-ons. Public evidence does not provide deal-vintage ROIC, so consolidated ROIC remains the controlling scorecard. The 2026 walkaway from a billion-dollar opportunity suggests improved price discipline.

Have there been significant acquisitions recently?

The major recent platform was ILC Dover, acquired for about $2.35 billion in 2024. It generated $265.8 million of ILC goodwill/intangible impairment in Q2-2025; a separate $120.9 million HPS equity-method impairment occurred in the same quarter. IR has agreed to $187.5 million of ILC-related insurance recovery and seeks more. In 2026 it bought Scinomix, Fox, and service businesses for $163.2 million through June; Lone Star Blowers and Fai Filtri add service/filter aftermarket. Early results are too limited to establish returns.

Is the company buying back shares or issuing large amounts to insiders?

IR repurchased about $1.02 billion in 2025 at an estimated average near $86 and $338.8 million in H1-2026; Q2 purchases averaged $71.13. Diluted adjusted shares fell 2.8% year over year, contributing about three percentage points of adjusted-EPS growth. Equity compensation exists, but the share count is falling rather than being materially diluted. Director Satpathy’s $1 million open-market purchase is the only 2026 code-P transaction in the mirrored corpus.

What is the compensation policy and what motivates management?

Annual incentives are 75% adjusted EPS and 25% FCF. Long-term grants are 50% relative-TSR performance shares, 25% RSUs, and 25% options. The 2025 annual payout was 69% of target; a special option tranche was forfeited when adjusted-EPS growth missed its hurdle. The design rewards growth, cash, and market performance but not ROIC. CEO compensation was $16.2 million in 2025. Management is motivated to compound per-share earnings and TSR; the concern is insufficient direct incentive to maximize return on acquisition capital.

Valuation & Market Data

Is the stock an ADR, MLP, or K-1 issuer? What is the dividend policy?

No. Ingersoll Rand Inc. is a U.S. corporation listed on the NYSE under IR. It is not an ADR, MLP, or K-1 issuer. The dividend is token at approximately $0.08 per share annually; buybacks and acquisitions are the primary capital-return channels.

How profitable is the business, and is net income diverging from operating cash flow?

TTM revenue is $7.94 billion, gross margin 42.8%, GAAP operating margin 18.1%, net income $959.1 million, and CFO $1.35 billion. CFO exceeds net income because acquisition amortization and other noncash charges are material. That divergence is not automatically low quality, but recurring amortization reflects the consumption of purchased intangibles. H1 cash lagged adjusted earnings and revenue growth, making working-capital conversion a current concern.

What does current valuation imply?

At $78.57, market capitalization is approximately $30.5 billion and EV $34.2 billion. That is about 17.4x reported TTM EBITDA, 16.2x adjusted TTM EBITDA, 4.3x sales, and 22.0x high-end 2026 adjusted EPS. A reverse DCF implies roughly 7–9% FCFF growth for ten years, far above the 1–3% organic revenue guide. The difference must come from margins, acquisitions, and cash deployment at returns above WACC.

Risks & Downside

What factors would cause the stock to decline?

The principal triggers are organic orders returning to zero or negative, failure of the H2 margin recovery, working-capital absorption, a large expensive platform acquisition, additional impairment, China price/cost deterioration, or industrial multiple compression. The stock remains below its 50- and 200-day EMAs and has experienced 30%–37% drawdowns despite strong operating improvement, so valuation can move sharply when the compounder narrative weakens.

Is there risk of catastrophic or total loss?

Catastrophic operating loss is low because revenue is diversified, aftermarket is material, liquidity is ample, leverage is moderate, and products are not dependent on a single patent or customer. Total equity loss is remote under current capital structure. The plausible severe-downside path is a large debt-funded acquisition followed by recession, impairment, and covenant/rating pressure. That would be a management-created balance-sheet event rather than a likely base-case industry outcome.

Recent News & Events

Has the business environment changed recently?

Yes. Q2-2026 organic revenue improved to 4.1%, P&ST orders accelerated, and July long-cycle orders closed after delays. At the same time, ITS margin contracted on China price/cost, growth investment, and mix. Peer industrial orders strengthened broadly, indicating a real market upswing but raising questions about IR’s relative ITS order momentum.

Have there been significant acquisitions, accounting changes, new markets, facilities, or management changes?

No material accounting-policy change alters the thesis. The important accounting events are the 2025 ILC/HPS impairments and 2026 insurance recovery, which must be separated from operating performance. Recent acquisitions are predominantly bolt-ons; management walked from a roughly $1 billion target. Michael Weatherred’s expanded P&ST leadership role and board additions including Satpathy and Jerome Guillen are relevant governance changes. Growth investment and prior China capacity are affecting current margin, but there is no evidence of a broad new-factory expansion cycle.

APPENDIX B — Source Appendix

Public Primary Sources

Company filings and investor materials

• Ingersoll Rand Inc., FY2025 Form 10-K, filed 2026-02-17. Used for business description, segment history, risk factors, acquisitions, debt, and FY2025 financial statements.
• Ingersoll Rand Inc., Q2-2026 Form 10-Q, filed 2026-07-31. Used for Q2/H1 financials, revenue bridges, cash flow, working capital, purchase accounting, goodwill/intangibles, ILC recovery, HPS distinction, and balance sheet.
• Ingersoll Rand Inc., Q2-2026 earnings release, Exhibit 99.1, filed 2026-07-30. Used for orders, organic growth, adjusted EBITDA, segment margins, guidance, capital deployment, and aftermarket data.
• Ingersoll Rand Inc., 2026 proxy statement, filed 2026-04-24. Used for incentive metrics, equity awards, ownership requirements, CEO compensation, and governance.
• Ingersoll Rand Inc., Aurobind Satpathy Form 4, filed 2026-08-05. Used for the 2026-08-03 open-market purchase.
• Ingersoll Rand Inc., ILC Dover acquisition announcement, filed 2024-03-25. Used for transaction context.
• Ingersoll Rand Inc., Q2-2025 results Form 8-K, filed 2025-07-31. Used for the impairment-period event and price-map cross-reference.
• Ingersoll Rand Inc., Q2-2024 results Form 8-K, filed 2024-07-31. Used for the five-year event map.
• Ingersoll Rand Inc., events and presentations archive, accessed 2026-08-26. Used for the Q2-2026 call/webcast and management commentary.
• Ingersoll Rand Inc., 2023 Investor Day presentation, dated 2023-03-30. Used for management-estimated market position, ITS TAM, installed-base strategy, and IRX framework.
• Ingersoll Rand Inc., Q4/FY2024 earnings presentation, dated 2025-02-14. Used for management-estimated portfolio TAM and acquisition framing.
• U.S. SEC, Ingersoll Rand company submissions and company facts, accessed 2026-08-26. Used to identify the issuer and reconcile filing history/XBRL facts.

Competitor and industry sources

• Atlas Copco Group, Q2-2026 financial report, published 2026-07-16. Used for Compressor Technique orders, revenue, margin, ROCE, and industry cross-read.
• Atlas Copco Group, 2025 Annual Report, published 2026-03-20. Used for Compressor Technique economics and acquisition activity.
• AMETEK, Inc., Q2-2026 earnings release, filed 2026-08-04. Used for peer organic sales, orders, and backlog.
• AMETEK, Inc., Indicor acquisition announcement, dated 2026-05-06. Used for acquisition-market pricing and strategic context.
• IDEX Corporation, Q2-2026 earnings release, published 2026-07-29. Used for peer organic growth and order cross-read.

Market, factor, and valuation data

• AZI Trading, IR adjusted daily price history, data through 2026-08-25, accessed 2026-08-26. Used for the five-year event map, current price, range, returns, and moving averages.
• AZI Trading, IR fundamentals endpoint, observation dated 2026-08-25, accessed 2026-08-26. Only the own-history valuation index was used.
• FactorsToday, public API observations for IR: stock loadings, leaderboard, stock information, stock-specific volatility, and related stocks, accessed 2026-08-26. Used for factor exposure, returns, drawdowns, beta, risk-adjusted performance, and peer similarity.
• ROIC.ai, Ingersoll Rand public company page, accessed 2026-08-26. Used as a directional cross-check for TTM statements, profitability, peer metrics, and the latest earnings-call record; filing-rebuilt values govern where definitions or period prices differ.
• ROIC.ai public company pages for AMETEK, Roper, Dover, IDEX, Parker-Hannifin, and Nordson, accessed 2026-08-26. Used for current peer-multiple and ROIC cross-checks with enterprise values rebuilt at current prices.

Source Limitations

• IR does not disclose product-level market-share history, installed-base counts, aftermarket attach or retention, or deal-vintage ROIC. Moat and acquisition-return conclusions therefore rely on segment economics, public competitor cross-reads, and goodwill-inclusive consolidated ROIC.
• The Q2 filing does not quantify price versus volume inside organic growth. China price/cost commentary is qualitative.
• The Atlas Copco order comparison is directionally relevant but not like-for-like because product, geography, and project timing differ.
• Third-party valuation and ROIC fields use different definitions and sometimes stale period-end prices. Current EV, FCF, and full-capital ROIC were rebuilt from filings and the August 25 market price.